KRAS and non-small cell lung carcinoma: We found coalterations in eight driver genes in 72.2% of NSCLC patients, namely, EGFR (e18–e21, 20.4% [11 of 54]), ALK (fusion, 7.4% [4 of 54], KRAS (p. G12/13/61, 37% [20 of 54]), BRAF (p. V600E, 13% [7 of 54]), ERBB2 (1.9% [1 of 54]), PIK3CA (p. E542/E545/H1047, 1.9% [1 of 54]), RET (0% [0 of 54]), and ROS1 (0% [0 of 54]).